Issues on the selection of non-inferiority margin in clinical trials

Chinese Medical Journal

Volumn 122, Issue 4, 2009, Pages 466-470

  Hou, Yan ^a   Wu, Xiao Yan ^a   Li, Kang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Clinical trial; Non inferiority; Non inferiority margin

Indexed keywords

ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIRETROVIRUS AGENT; ANTIRHEUMATIC AGENT; FIBRINOLYTIC AGENT; URINARY TRACT ANTIINFECTIVE AGENT; VACCINE;

ANALYTICAL ERROR; CHINA; CLINICAL STUDY; DATA ANALYSIS; DATA EXTRACTION; DRUG SAFETY; MATHEMATICAL COMPUTING; MEDICAL LITERATURE; MEDLINE; NON INFERIORITY MARGIN; REVIEW; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS; CLINICAL TRIAL; METHODOLOGY; STATISTICAL MODEL; STATISTICS;

CLINICAL TRIALS AS TOPIC; MODELS, STATISTICAL; RESEARCH DESIGN;

EID: 65649154631     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.04.0020     Document Type: Review

References (43)

1. Guidance on choice of control group and related design and conduct issues in clinical trials. US Food and Drug Administration, 2001. (Assessed May 14, 2001 at http://www.fda.gov/cder/guidance/ 4155fnl.pdf)
2. Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections. London: Committee For Proprietary Medicinal Products, 2004. (Assessed April 22, 2004 at http://www.emea.europa.eu/pdfs/human/ewp/055895en.pdf)
3. Note for guidance on clinical investigation of medicinal products in the treatment of hypertension. London: Committee For Proproetary Medicinal Products, 2004. (Accessed June 23, 2004 at http://www.tga.health.gov.au/docs/pdf/euguide/ewp/023895r2.pdf)
4. Point to consider on clinical investigation of medicinal products used in the treatment of nociceptive pain. London: Committee For Proprietary Medicinal Products, 2002 (Accessed 21 November, 2002 at http://www.tga.gov.au/docs/pdf/euguide/ewp/078497en.pdf)
5. Guideline on the choice of the non-inferiority margin. London: Committee For Proprietary Medicinal Products, 2005. (Accessed July 27, 2005 at http://www.emea.europa.eu/pdfs/human/ewp/215899en.pdf)
6. Note for guidance on the clinical evaluation of vaccines. London: Committee For Proprietary Medicinal Products, 2005. (Accessed 17 May, 2005 at http://www.emea.europa.eu/pdfs/human/vwp/16465305en.pdf)
7. Point to consider on switching between superiority and non-inferiority. London: Committee For Proprietary Medicinal Products, 2000. (Accessed July 27, 2000 at http://www.tga.gov.au/docs/pdf/euguide/ewp/ 048299En.pdf)
8. Points to consider on the choice of non-inferiority margin (draft). London: Committee For Proprietary Medicinal Products, 2004. (Accessed February 26, 2004 at http://home.att.ne.jp/red/akihiro/emea/ 215899en_ptc.pdf)
9. Tsou HH, Hsiao CF, Chow SC, Yue L, Xu Y, Lee S. Mixed noninferiority margin and statistical tests in active controlled trials. J Biopharm Stat 2007; 17: 339-357.
10. Blackwelder WC. Proving the null hypothesis in clinical trials. Control Clin Trials 1982; 3: 345-353.
11. Tsong Y, Higgins K, Wang SJ, Hung HM. An overview of equivalence testing-CDER reviewers' perspective. P Biopharm Sec Am Stat Assoc 1999; 214-219.
12. Hung HM, Wang SJ, Tsong Y, Lawrence J, O'Neill RT. Some fundamental issues with non-inferiority testing in active controlled clinical trials. Stat Med 2003; 22: 212-225.
13. Hung HMJ, Wang SJ, O'Neill RT. A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials. Biometrical J 2005; 47: 28-36.
14. Lange S, Freitag G. Special invited papers section: therapeutic equivalence-clinical issues and statistical methodology in noninferiority trials. Biometrical J 2005; 47: 12-27.
15. Simon R. Bayesian design and analysis of active control clinical trials. Biometrics 1999; 55: 484-487.
16. Holmgren EB. Establishing equivalence by showing that a prespecified percentage of the effect of the active control over placebo is maintained. J Biopharm Stat 1999; 9: 651-659.
17. Wang SJ, Hung HM, Tsong Y. Utility and pitfall of some statistical methods in active controlled clinical trials. Control Clin Trials 2002; 23: 15-28.
18. Hasselblad V, Kong DF. Statistical methods for comparison to placebo in active-control trials. Drug Inf J 2001; 35: 435-449.
19. Wang SJ, Hung HM. Assessment of treatment efficacy in the non-inferiority trials. Control Clin Trials 2003; 24: 147-155.
20. Rothmann M, Li N, Chen G, Chi GY, Temple R, Tsou HH. Design and analysis of non-inferiority mortality trials in oncology. Stat Med 2003; 22: 239-264.
21. Wang SJ, Hung HM. TACT method for non-inferiority testing in active controlled trials. Stat Med 2003; 22: 227-238.
22. Rothmann M, Li N, Chen G, Chi GY, Tsong HH. Non-inferiority methods for mortality trials. Annual Meeting of the American Statistical Association, Alexandria, USA, 2001.
23. Chow SC, Shao J. On noinferiority margin and statistical tests in active control trials. Stat Med 2006; 25: 101-111.
24. Wei X, Chappell R. A test for noninferiority with a mix multiplicative/ additive null hypothesis. Presentation in ENAR Spring Meeting, Austin, England, 2005.
25. Lesaffre E, Bluhmki E, Wang CF, Berioli S, Danays T, Fox NL, et al. The general concepts of an equivalence trial, applied to ASSENT-2, a large-scale mortality study comparing two fibrinolytic agents in acute myocardial infarction. J Eur Heart 2001; 22: 898-902.
26. Clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis. US Food and Drug Administration, 1999. (Accessed February, 1999 at http://www.fda.gov/ cder/guidance/raguide.pdf)
27. Points to consider. Clinical development and labeling of anti-infective drug products. US Food and Drug Administration, 1997. (Accessed February, 1997 at http://www.fda.gov/cder/guidance/old043fn.pdf)
28. Complicated urinary tract infections and pyelonephritis-developing antimicrobial drugs. US Food and Drug Administration, 1998. (Accessed July, 1998 at http://www.fda.gov/cder/guidance/2559dft.htm)
29. Antiretroviral drugs using plasma HIV RNA measurements-clinical considerations for accelerated and traditional approval. US Food and Drug Administration, 2002 (Accessed October, 2002 at http://www.fda.gov/cder/Guidance/3647fnl.pdf)
30. Proskin HM, Kingman A, Naleway C, Woznaik WT. Comparative attributes for the description of the relative efficacy of therapeutic agents: general concepts and definitions, and application to the American Dental Association guidelines for the comparison of the clinical anticaries efficacy of fluoride dentifrices. J Clin Dent 1995; 6: 176-184.
31. Guidelines for the clinical evaluation of anti-inflammatory and anti-rheumatic drugs. US Food and Drug Administration, 1988. (Accessed at http://www.fda.gov/cder/guidance/raguide.pdf)
32. Unknown. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998; 39: 799-803.
33. Note for guidance on clinical evaluation of new vaccines. US Food and Drug Administration, 2005. (Accessed May 17, 2005 at http://www.emea.europa.eu/pdfs/human/vwp/16465305en.pdf
34. InTIME-II Investigators. Intravenous NPA for the treatment of infarct in myocardium early; InTime-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21: 2005-2013.
35. Liu YX, Yao C, Chen F, Chen QG, Su BH, Sun RY. Statistical issues in Noninferiority/Equivalence Trials. Chin J Clin Pharmacol Ther (Chin) 2000; 5: 334-338.
36. Liu YX, Yao C, Chen F, Chen QG, Su BH, Sun RY. Statistical issues in noninferiority/equivalence trials. Chin J Clin Pharmacol (Chin) 2000; 16: 448-452.
37. Huang Q, Zhao M. Considerations on the statistical hypothesis of noninferiority, equivalence and superiority design in clinical trial. Chin J Clin Pharmacol (Chin) 2007; 23: 63-67.
38. Zhao C, Li J, Hou J, Guo M, Zhang Y, Chen Y. A randomized controlled clinical trial on etimicin, a new aminoglycoside antibiotic, versus netilmicin in the treatment of bacterial infections. Chin Med J 2000; 113: 1026-1030.
39. Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, et al. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial. Chin Med J 2003; 116: 1228-1234.
40. Quan W, Lu G, Qi W, Li Y, Shen Y, Yuan R. Diagnostic value of magnetocardiography in patients with coronary heart disease and in-stent restenosis. Chin Med J 2008; 121: 22-26.
41. Liu H, Xu B, Gao R, Yang Y, Yao M, Qin X, et al. Outcomes of using Firebird rapamycin eluting stents in routine coronary intervention practice: one-year results from the pilot study of Firebird in China registry. Chin Med J 2006; 119: 609-611.
42. Zhou C, Fang Y, Jiang D, Yang S, Lu X, Sui J, et al. Preclinical trials of human erythrocyte superoxide dismutase injection. Chin Med J 2000; 113: 654-656.
43. Heeg MJ, Deutsch KF, Deutsch E. The placebo effect. Eur J Nucl Med 1997; 24: 1433-1440.